Abiopharma

🔍 Wilm Renee L (Executive)

Company: Liberty Broadband Corp (LBRDK)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Sold 12,312 shares of Series C Common Stock (Direct)
  Date: 2026-08-19 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 26,989 shares of Stock Option - LBRDK (Right to Buy) at $110.25 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2026-11-04 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 19,445 shares of Stock Option - LBRDK (Right to Buy) at $118.15 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2026-11-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 5,227 shares of Stock Option - LBRDK (Right to Buy) at $153.39 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2027-12-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 8,138 shares of Stock Option - LBRDK (Right to Buy) at $153.58 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2027-12-07 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 23,606 shares of Stock Option - LBRDK (Right to Buy) at $71.17 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2030-12-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 63,917 shares of Stock Option - LBRDK (Right to Buy) at $72.31 per share (Derivative)
  Date: 2026-08-19 | Code: D | Expires: 2030-12-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: Pursuant to the terms of the Merger Agreement (as defined in the Remarks section), at the effective time of the Merger (as defined in the Remarks section), each share of the Issuer's Series C Common Stock issued and outstanding immediately prior to the effective time of the Merger was automatically converted into 0.2360 of a share of Charter Communications, Inc. ("Charter") Class A Common Stock, except that cash (without interest) was paid in lieu of fractional shares.
• F2: These options were fully exercisable.
• F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, such stock option of the Issuer was cancelled for no consideration.
• REMARKS: Pursuant to the Agreement and Plan of Merger, dated as of November 12, 2024 (the "Merger Agreement"), by and among the Issuer, Charter, Fusion Merger Sub 1, LLC, a Delaware limited liability company and wholly owned subsidiary of Charter ("Merger LLC"), and Fusion Merger Sub 2, Inc., a Delaware corporation and wholly owned subsidiary of Merger LLC ("Merger Sub"), on August 19, 2026, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Merger LLC, and immediately following the Merger, the Issuer (as the surviving corporation in the Merger) merged with and into Merger LLC (the "Upstream Merger") with Merger LLC surviving the Upstream Merger as the surviving company and a wholly owned subsidiary of Charter.